The briefing
News-Medical reports on Enlicitide as a potential oral treatment option for patients who prefer to avoid injectable PCSK9 inhibitors, a class first approved in 2015 after UT Southwestern-led research. The piece discusses how an oral approach could broaden cholesterol-lowering choices.
Original headline
Enlicitide offers oral treatment option for patients avoiding cholesterol injections